See more : Navarre Minerals Limited (NML.AX) Income Statement Analysis – Financial Results
Complete financial analysis of Mersana Therapeutics, Inc. (MRSN) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Mersana Therapeutics, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- IDP Education Limited (IEL.AX) Income Statement Analysis – Financial Results
- TravelCenters of America LLC 8% SR NT 2030 (TANNZ) Income Statement Analysis – Financial Results
- Ackermans & Van Haaren NV (AVHNY) Income Statement Analysis – Financial Results
- Shanghai Fengyuzhu Culture Technology Co., Ltd. (603466.SS) Income Statement Analysis – Financial Results
- Amylyx Pharmaceuticals, Inc. (AMLX) Income Statement Analysis – Financial Results
Mersana Therapeutics, Inc. (MRSN)
About Mersana Therapeutics, Inc.
Mersana Therapeutics, Inc., a clinical stage biopharmaceutical company, develops antibody drug conjugates (ADC) for cancer patients with unmet need. It develops XMT-1592, a Dolasynthen ADC targeting NaPi2b-expressing tumor cells, which is in phase I clinical trial for the treatment of ovarian cancer and NSCLC adenocarcinoma. The company also develops XMT-1660, a B7-H4-targeted Dolasynthen ADC candidate; and XMT-2056, an immunosynthen development candidate. It has a strategic research and development partnerships with Merck KGaA and Asana BioSciences, LLC for the development of ADC product candidates utilizing Fleximer. The company was formerly known as Nanopharma Corp. and changed its name to Mersana Therapeutics, Inc. in November 2005. Mersana Therapeutics, Inc. was incorporated in 2001 and is headquartered in Cambridge, Massachusetts.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 36.86M | 26.58M | 43.00K | 828.00K | 42.12M | 10.59M | 17.55M | 25.17M | 10.36M |
| Cost of Revenue | 148.27M | 927.00K | 132.01M | 67.04M | 55.04M | 59.92M | 928.00K | 32.01M | 21.35M |
| Gross Profit | -111.41M | 25.65M | -131.97M | -66.21M | -12.92M | -49.32M | 16.62M | -6.84M | -10.99M |
| Gross Profit Ratio | -302.30% | 96.51% | -306,906.98% | -7,996.14% | -30.66% | -465.56% | 94.71% | -27.16% | -106.13% |
| Research & Development | 148.27M | 173.39M | 132.01M | 67.04M | 55.04M | 59.92M | 46.70M | 32.01M | 21.35M |
| General & Administrative | 59.54M | 56.96M | 36.89M | 21.90M | 17.28M | 16.33M | 10.46M | 6.98M | 5.35M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 59.54M | 56.96M | 36.89M | 21.90M | 17.28M | 16.33M | 10.46M | 6.98M | 5.35M |
| Other Expenses | 0.00 | -445.00K | -1.20M | 0.00 | 0.00 | 1.40M | 0.00 | 0.00 | -89.00K |
| Operating Expenses | 36.86M | 230.35M | 168.90M | 88.94M | 72.32M | 76.25M | 57.16M | 38.99M | 26.70M |
| Cost & Expenses | 207.81M | 230.35M | 168.90M | 88.94M | 72.32M | 76.25M | 57.16M | 38.99M | 26.70M |
| Interest Income | 12.07M | 2.88M | 65.00K | 424.00K | 2.23M | 1.40M | 910.00K | 121.00K | 2.00K |
| Interest Expense | 4.07M | 3.33M | 1.27M | 359.00K | 234.00K | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 1.52M | 927.00K | 855.00K | 1.01M | 1.25M | 1.26M | 928.00K | 655.00K | 297.00K |
| EBITDA | -166.08M | -199.96M | -167.94M | -86.68M | -26.73M | -63.00M | -37.78M | -13.17M | -16.04M |
| EBITDA Ratio | -450.63% | -766.59% | -392,693.02% | -10,468.12% | -66.41% | -619.74% | -220.51% | -52.31% | -154.88% |
| Operating Income | -170.96M | -204.69M | -169.71M | -87.69M | -29.22M | -65.66M | -39.62M | -13.82M | -16.34M |
| Operating Income Ratio | -463.86% | -770.08% | -394,681.40% | -10,590.10% | -69.37% | -619.74% | -225.80% | -54.91% | -157.75% |
| Total Other Income/Expenses | -713.00K | -445.00K | -1.20M | 65.00K | 1.99M | 1.40M | 910.00K | 121.00K | -87.00K |
| Income Before Tax | -171.67M | -204.21M | -170.06M | -88.05M | -28.21M | -64.26M | -38.71M | -13.70M | -16.43M |
| Income Before Tax Ratio | -465.80% | -768.26% | -395,488.37% | -10,633.45% | -66.97% | -606.54% | -220.62% | -54.43% | -158.59% |
| Income Tax Expense | 0.00 | 3.33M | -855.00K | 359.00K | -1.01M | 1.40M | 0.00 | 0.00 | -2.00K |
| Net Income | -171.67M | -207.54M | -169.21M | -88.40M | -27.20M | -64.26M | -38.71M | -13.70M | -16.43M |
| Net Income Ratio | -465.80% | -780.78% | -393,500.00% | -10,676.81% | -64.57% | -606.54% | -220.62% | -54.43% | -158.59% |
| EPS | -1.48 | -2.22 | -2.40 | -1.44 | -0.63 | -2.79 | -3.22 | -0.78 | -0.94 |
| EPS Diluted | -1.48 | -2.22 | -2.40 | -1.44 | -0.63 | -2.79 | -3.22 | -0.78 | -0.94 |
| Weighted Avg Shares Out | 116.11M | 93.65M | 70.58M | 61.49M | 43.40M | 23.03M | 12.02M | 17.49M | 17.49M |
| Weighted Avg Shares Out (Dil) | 116.11M | 93.65M | 70.58M | 61.49M | 43.49M | 23.03M | 12.02M | 17.49M | 17.49M |
Mersana Therapeutics, Inc. (MRSN) Q3 2024 Earnings Call Transcript
Mersana Therapeutics, Inc. (NASDAQ:MRSN ) Q3 2024 Earnings Conference Call November 13, 2024 8:00 AM ET Company Participants Jason Fredette - SVP, IR Martin Huber - President & CEO Mohan Bala - SVP, Chief Development Officer Brian DeSchuytner - CFO...
Mersana Therapeutics, Inc. (MRSN) Reports Q3 Loss, Tops Revenue Estimates
Mersana Therapeutics, Inc. (MRSN) came out with a quarterly loss of $0.09 per share versus the Zacks Consensus Estimate of a loss of $0.18. This compares to loss of $0.35 per share a year ago.
Mersana Therapeutics Provides Business Update and Announces Third Quarter 2024 Financial Results
CAMBRIDGE, Mass., Nov. 13, 2024 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today provided a...
Mersana Therapeutics to Host Third Quarter 2024 Conference Call on November 13, 2024
CAMBRIDGE, Mass., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced that...
Mersana Therapeutics, Inc. (MRSN) Reports Q2 Loss, Misses Revenue Estimates
Mersana Therapeutics, Inc. (MRSN) came out with a quarterly loss of $0.20 per share versus the Zacks Consensus Estimate of a loss of $0.18. This compares to loss of $0.47 per share a year ago.
Mersana Therapeutics Provides Business Update and Announces Second Quarter 2024 Financial Results
CAMBRIDGE, Mass., Aug. 13, 2024 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today provided a...
Mersana Therapeutics to Host Second Quarter 2024 Conference Call on August 13, 2024
CAMBRIDGE, Mass., Aug. 06, 2024 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced that...
Mersana Therapeutics to Present at Upcoming Investor Conferences
CAMBRIDGE, Mass., May 22, 2024 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced that...
Mersana Therapeutics, Inc. (MRSN) Q1 2024 Earnings Call Transcript
Mersana Therapeutics, Inc. (NASDAQ:MRSN ) Q1 2024 Earnings Conference Call May 9, 2024 8:00 AM ET Company Participants Jason Fredette - Senior Vice President, Investor Relations & Corporate Communications Martin Huber - President & Chief Executive Officer Brian DeSchuytner -...
Mersana Therapeutics, Inc. (MRSN) Reports Q1 Loss, Misses Revenue Estimates
Mersana Therapeutics, Inc. (MRSN) came out with a quarterly loss of $0.16 per share versus the Zacks Consensus Estimate of a loss of $0.18. This compares to loss of $0.52 per share a year ago.
Source: https://incomestatements.info
Category: Stock Reports